Evidence map›Paper›PMID 41801884›Full record

ArticlePloS one2026

Minigenes for heterologous expression of human and mouse cationic trypsinogen.

Gergő Berke, Miklós Sahin-Tóth

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gergő BerkeDepartment of Surgery, University of California Los Angeles, Los Angeles, California, United States of America.
Miklós Sahin-TóthDepartment of Surgery, University of California Los Angeles, Los Angeles, California, United States of America.ORCID https://orcid.org/0000-0003-4513-9922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inborn mutations in the PRSS1 gene encoding human cationic trypsinogen cause hereditary pancreatitis. In mouse models, PRSS1 mutations are often studied in the context of the Prss3b gene that codes for mouse cationic trypsinogen. To characterize the cellular and biochemical effects of trypsinogen mutations, heterologous expression in transfected cell lines is often employed. Recent studies with the human and mouse trypsin inhibitor SPINK1 indicated that minigene expression constructs carrying a short intron yield markedly higher recombinant protein levels than cDNA constructs. Here, we investigated whether the minigene approach would increase the expression of human and mouse cationic trypsinogen in transfected HEK 293T cells. We found that compared with the cDNA, minigene constructs increased PRSS1 and Prss3b mRNA levels by 2.5-fold and 4.5-fold on average, respectively. Surprisingly, however, the amount of secreted human cationic trypsinogen remained unchanged while secretion of mouse cationic trypsinogen was increased 2.9-fold. The observations indicate that minigene expression constructs are effective in boosting mRNA levels in transfected cells, however, this may not always translate to elevated protein secretion. In these cases, inefficient protein translation and/or folding may be rate limiting.

Indexed as

TrypsinTrypsinogenAnimalsHEK293 CellsHumansMiceRNA, MessengerTransfectionPRSS1 protein, humanPRSS3 protein, humanRNA, MessengerTrypsinTrypsinogen

Identifiers

PMID41801884
PMCPMC12970870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.